Bristol-Myers Squibb Company (NYSE:BMY)
Market Cap | 142.35B |
---|---|
Revenue | 46.16B |
Gross Profit | 36.02B |
Shares Out | 2.10B |
EPS (ttm) | 2.95 |
PE Ratio | 22.4991 |
Forward PE | 8.3787 |
Dividend Rate (ttm) | 2.1655 |
Dividend Yield | 0.0320 |
Trading Day | Mar 24 |
---|---|
Last Price | $67.68 |
Previous Close | $66.98 |
Change ($) | 0.7 |
Change (%) | 1.04% |
Day's Open | 67.2 |
Day's Range | 66.69 - 67.775 |
Day's Volume | 6.28M |
52 Week Range | 64.94 - 80.8 |
About Bristol-Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
News
Quick info
New York
New York
10016-8367
Bristol-Myers Squibb Company income statements (2022) (USD)
July 2022 | July 2022 | April 2022 | February 2022 | |
---|---|---|---|---|
Total Revenue | 11.89B | 11.89B | 11.65B | 11.99B |
Cost of Revenue | 2.72B | 2.72B | 2.47B | 2.36B |
Gross Profit | 9.17B | 9.17B | 9.18B | 9.63B |
Research & Development | 2.32B | 2.32B | 2.26B | 2.61B |
Selling General & Admin | 1.79B | 1.79B | 1.83B | 2.35B |
Operating Expense | 9.25B | 9.25B | 8.98B | 9.73B |
Operating Income | 2.64B | 2.64B | 2.67B | 2.25B |
Other Income Expense Net | 0 | 0 | 0 | 0 |
EBIT | 2.33B | 2.33B | 2.03B | 1.04B |
Interest Income | 313M | 313M | 326M | 323M |
Pretax Income | 1.96B | 1.96B | 1.69B | 1.86B |
Income Tax | 529M | 529M | 404M | -514M |
Minority Interest | 8M | 8M | 5M | 0 |
Net Income | 1.42B | 1.42B | 1.28B | 2.37B |
Net Income Basic | 1.42B | 1.42B | 1.28B | 2.37B |
Bristol-Myers Squibb Company income statements (2021) (USD)
October 2021 | October 2021 | July 2021 | April 2021 | February 2021 | |
---|---|---|---|---|---|
Total Revenue | 11.62B | 11.62B | 11.70B | 11.07B | 11.07B |
Cost of Revenue | 2.29B | 2.29B | 2.45B | 2.84B | 2.91B |
Gross Profit | 9.33B | 9.33B | 9.25B | 8.23B | 8.16B |
Research & Development | 3.25B | 3.25B | 3.27B | 2.23B | 3.75B |
Selling General & Admin | 1.79B | 1.79B | 1.88B | 1.67B | 2.72B |
Operating Expense | 9.88B | 9.88B | 10.15B | 9.25B | 11.89B |
Operating Income | 1.75B | 1.75B | 1.55B | 1.83B | -820M |
Other Income Expense Net | 0 | 0 | 0 | 0 | 0 |
EBIT | 2.21B | 2.21B | 1.70B | 2.43B | -1.64B |
Interest Income | 328M | 328M | 330M | 353M | 355M |
Pretax Income | 2.16B | 2.16B | 1.55B | 2.53B | -10.45B |
Income Tax | 605M | 605M | 492M | 501M | -424M |
Minority Interest | 6M | 6M | 6M | 8M | 0 |
Net Income | 1.55B | 1.55B | 1.06B | 2.02B | -10.03B |
Net Income Basic | 1.55B | 1.55B | 1.06B | 2.02B | -10.03B |
Bristol-Myers Squibb Company income statements (2020) (USD)
August 2020 | June 2020 | March 2020 | |
---|---|---|---|
Total Revenue | 10.13B | 10.13B | 10.78B |
Cost of Revenue | 2.70B | 5.08B | 5.93B |
Gross Profit | 7.43B | 5.05B | 4.85B |
Research & Development | 2.52B | 2.48B | 2.32B |
Selling General & Admin | 1.63B | 1.63B | 1.61B |
Operating Expense | 9.24B | 9.19B | 9.85B |
Operating Income | 891M | 0.94B | 0.93B |
Other Income Expense Net | 361M | 688M | -1.23B |
EBIT | 2.07B | 0.94B | 0.93B |
Interest Income | 357M | 357M | 362M |
Pretax Income | 1.63B | 1.63B | -304M |
Income Tax | 1.71B | 1.71B | 462M |
Minority Interest | 5M | 5M | 9M |
Net Income | -85M | -85M | -775M |
Net Income Basic | -85M | -85M | -775M |
Bristol-Myers Squibb Company income statements (2019) (USD)
December 2019 | September 2019 | June 2019 | March 2019 | |
---|---|---|---|---|
Total Revenue | 7.95B | 6.01B | 6.27B | 5.92B |
Cost of Revenue | 3.53B | 1.79B | 1.87B | 1.83B |
Gross Profit | 4.42B | 4.22B | 4.40B | 4.09B |
Research & Development | 1.99B | 1.36B | 1.31B | 1.30B |
Selling General & Admin | 1.73B | 1.06B | 1.08B | 1.01B |
Operating Expense | 7.24B | 4.21B | 4.26B | 4.14B |
Operating Income | 701M | 1.80B | 2.02B | 1.78B |
Other Income Expense Net | -830M | -453M | -242M | 196M |
EBIT | 701M | 1.80B | 2.02B | 1.78B |
Interest Income | 279M | 209M | 123M | 45M |
Pretax Income | -129M | 1.35B | 1.78B | 1.98B |
Income Tax | 0.93B | -17M | 337M | 264M |
Minority Interest | -4M | 13M | 7M | 5M |
Net Income | -1.06B | 1.35B | 1.43B | 1.71B |
Net Income Basic | -1.06B | 1.35B | 1.43B | 1.71B |
Bristol-Myers Squibb Company income statements (2018) (USD)
December 2018 | September 2018 | June 2018 | March 2018 | |
---|---|---|---|---|
Total Revenue | 5.97B | 5.69B | 5.70B | 5.19B |
Cost of Revenue | 1.69B | 1.65B | 1.60B | 1.59B |
Gross Profit | 4.29B | 4.04B | 4.11B | 3.60B |
Research & Development | 1.36B | 1.26B | 2.42B | 1.23B |
Selling General & Admin | 1.34B | 1.10B | 1.13B | 0.98B |
Operating Expense | 4.38B | 4.01B | 5.15B | 3.80B |
Operating Income | 1.59B | 1.68B | 559M | 1.39B |
Other Income Expense Net | -43M | 490M | -42M | 386M |
EBIT | 1.59B | 1.68B | 559M | 1.39B |
Interest Income | 48M | 44M | 45M | 46M |
Pretax Income | 1.55B | 2.17B | 517M | 1.78B |
Income Tax | 357M | 255M | 135M | 284M |
Minority Interest | -2M | 11M | 9M | 9M |
Net Income | 1.19B | 1.90B | 373M | 1.49B |
Net Income Basic | 1.19B | 1.90B | 373M | 1.49B |
Bristol-Myers Squibb Company income statements (2017) (USD)
December 2017 | September 2017 | June 2017 | |
---|---|---|---|
Total Revenue | 5.45B | 5.25B | 5.14B |
Cost of Revenue | 1.48B | 1.56B | 1.39B |
Gross Profit | 3.97B | 3.69B | 3.76B |
Research & Development | 1.39B | 1.48B | 1.09B |
Selling General & Admin | 1.30B | 1.15B | 1.17B |
Operating Expense | 4.17B | 4.19B | 3.64B |
Operating Income | 1.28B | 1.06B | 1.50B |
Other Income Expense Net | -579M | 119M | -207M |
EBIT | 1.28B | 1.06B | 1.50B |
Interest Income | 51M | 48M | 52M |
Pretax Income | 698M | 1.18B | 1.30B |
Income Tax | 3.03B | 327M | 373M |
Minority Interest | -1M | 11M | 6M |
Net Income | -2.33B | 845M | 0.92B |
Net Income Basic | -2.33B | 845M | 0.92B |
Bristol-Myers Squibb Company balance sheet (2022) (USD)
July 2022 | July 2022 | April 2022 | February 2022 | |
---|---|---|---|---|
Current Cash | 13.27B | 13.27B | 15.20B | 17.22B |
Receivables | 9.05B | 9.05B | 8.51B | 9.37B |
Inventory | 2.14B | 2.14B | 2.10B | 2.10B |
Current Assets | 30.19B | 30.19B | 30.12B | 33.26B |
Other Current Assets | 5.57B | 5.57B | 4.16B | 4.44B |
Short Term Investments | 5.57B | 5.57B | 4.16B | 4.44B |
Long Term Investments | 70.17B | 70.17B | 72.91B | 76.05B |
Property/Plant Equipment | 5.97B | 5.97B | 6.05B | 6.05B |
Good Will | N.A | N.A | N.A | N.A |
Intangible Assets | 37.69B | 37.69B | 40.10B | 42.53B |
Tangible Assets (Net) | -25.54B | -25.54B | -29.02B | -27.08B |
Other Assets | 1.86B | 1.86B | 1.48B | 1.71B |
Total Assets | 100.36B | 100.36B | 103.03B | 109.31B |
Accounts Payable | 2.88B | 2.88B | 2.94B | 2.95B |
Other Current Liabilities | 13.08B | 13.08B | 12.36B | 13.97B |
Total Current Liabilities | 20.92B | 20.92B | 22.82B | 21.87B |
Total Liabilities | 67.76B | 67.76B | 71.45B | 73.37B |
Long Term Debt | 37.11B | 37.11B | 37.45B | 39.61B |
Current Long Term Debt | 4.95B | 4.95B | 7.52B | 4.95B |
Minority Interest | 61M | 61M | 65M | 60M |
Common Stock | 2.13B | 2.13B | 2.15B | 2.20B |
Treasury Stock | -35.29B | -35.29B | -35.19B | -31.26B |
Retained Earnings | 24.22B | 24.22B | 23.95B | 23.82B |
Capital Surplus | N.A | N.A | N.A | N.A |
Shareholder Equity | 32.60B | 32.60B | 31.58B | 35.95B |
Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2021) (USD)
October 2021 | October 2021 | July 2021 | April 2021 | February 2021 | |
---|---|---|---|---|---|
Current Cash | 15.66B | 15.66B | 14.02B | 12.93B | 16.45B |
Receivables | 9.25B | 9.25B | 9.02B | 8.66B | 8.50B |
Inventory | 2.16B | 2.16B | 2.14B | 1.95B | 2.07B |
Current Assets | 31.28B | 31.28B | 29.16B | 26.90B | 30.19B |
Other Current Assets | 4.07B | 4.07B | 3.82B | 3.22B | 3.17B |
Short Term Investments | 4.07B | 4.07B | 3.82B | 3.22B | 3.17B |
Long Term Investments | 79.61B | 79.61B | 81.64B | 85.53B | 88.29B |
Property/Plant Equipment | 5.87B | 5.87B | 5.80B | 5.76B | 5.89B |
Good Will | N.A | N.A | N.A | N.A | N.A |
Intangible Assets | 44.93B | 44.93B | 48.07B | 50.82B | 53.24B |
Tangible Assets (Net) | -28.24B | -28.24B | -31.79B | -33.74B | -35.97B |
Other Assets | 1.50B | 1.50B | 1.63B | 1.74B | 1.75B |
Total Assets | 110.89B | 110.89B | 110.80B | 112.44B | 118.48B |
Accounts Payable | 2.70B | 2.70B | 3.61B | 2.97B | 2.71B |
Other Current Liabilities | 13.70B | 13.70B | 12.73B | 12.58B | 14.03B |
Total Current Liabilities | 21.46B | 21.46B | 18.99B | 17.33B | 19.08B |
Total Liabilities | 73.68B | 73.68B | 73.99B | 74.83B | 80.66B |
Long Term Debt | 39.68B | 39.68B | 42.50B | 44.51B | 48.34B |
Current Long Term Debt | 5.07B | 5.07B | 2.66B | 1.78B | 2.34B |
Minority Interest | 71M | 71M | 66M | 68M | 60M |
Common Stock | 2.22B | 2.22B | 2.23B | 2.24B | 2.25B |
Treasury Stock | -28.57B | -28.57B | -28.2B | -27.2B | -26.24B |
Retained Earnings | 22.63B | 22.63B | 22.17B | 22.20B | 21.28B |
Capital Surplus | N.A | N.A | N.A | N.A | N.A |
Shareholder Equity | 37.21B | 37.21B | 36.81B | 37.61B | 37.82B |
Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2020) (USD)
August 2020 | June 2020 | March 2020 | |
---|---|---|---|
Current Cash | 21.66B | 20.02B | 15.82B |
Receivables | 7.86B | 6.70B | 7.20B |
Inventory | 2.38B | 2.38B | 2.84B |
Current Assets | 34.34B | 34.34B | 31.85B |
Other Current Assets | 2.45B | 1.29B | 1.41B |
Short Term Investments | 2.45B | 1.86B | 2.51B |
Long Term Investments | 93.73B | 5.20B | 2.96B |
Property/Plant Equipment | 5.78B | 6.48B | 6.84B |
Good Will | N.A | N.A | N.A |
Intangible Assets | 59.17B | 59.17B | 61.67B |
Tangible Assets (Net) | -30.66B | -60.07B | -63.07B |
Other Assets | 1.67B | 1.22B | 2.91B |
Total Assets | 128.08B | 128.08B | 129.29B |
Accounts Payable | 2.85B | 2.85B | 3.07B |
Other Current Liabilities | 15.75B | 13.34B | 10.17B |
Total Current Liabilities | 23.42B | 23.42B | 19.23B |
Total Liabilities | 78.98B | 78.92B | 79.31B |
Long Term Debt | 41.85B | 42.56B | 43.53B |
Current Long Term Debt | 4.82B | 4.25B | 3.26B |
Minority Interest | 66M | 5M | 9M |
Common Stock | 44.74B | 2.25B | 2.26B |
Treasury Stock | -25.65B | 25.65B | 24.76B |
Retained Earnings | 31.57B | 31.57B | 32.67B |
Capital Surplus | N.A | 44.44B | 43.25B |
Shareholder Equity | 49.09B | 49.09B | 49.91B |
Other Liabilities | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2019) (USD)
December 2019 | September 2019 | June 2019 | March 2019 | |
---|---|---|---|---|
Current Cash | 12.35B | 30.49B | 28.40B | 7.34B |
Receivables | 6.48B | 4.29B | 4.50B | 4.65B |
Inventory | 4.29B | 1.19B | 1.31B | 1.28B |
Current Assets | 29.35B | 40.19B | 37.72B | 17.09B |
Other Current Assets | 1.23B | 0.95B | 1.38B | 1.29B |
Short Term Investments | 3.05B | 2.05B | 0.95B | 1.43B |
Long Term Investments | 4.56B | 1.19B | 1.49B | 1.36B |
Property/Plant Equipment | 6.96B | 5.33B | 5.36B | 5.51B |
Good Will | N.A | N.A | N.A | N.A |
Intangible Assets | 63.97B | 1B | 1B | 1.03B |
Tangible Assets (Net) | -61.48B | 525M | -1.06B | -1.87B |
Other Assets | 2.11B | 1.59B | 1.63B | 1.91B |
Total Assets | 129.94B | 57.43B | 55.16B | 34.83B |
Accounts Payable | 2.45B | 1.89B | 2.01B | 1.98B |
Other Current Liabilities | 10.86B | 7.42B | 6.73B | 5.92B |
Total Current Liabilities | 18.30B | 10.49B | 9.71B | 8.84B |
Total Liabilities | 78.25B | 39.68B | 39.01B | 19.52B |
Long Term Debt | 44.06B | 24.89B | 24.95B | 6.16B |
Current Long Term Debt | 2.76B | N.A | N.A | N.A |
Minority Interest | -4M | 13M | 7M | 5M |
Common Stock | 2.23B | 1.63B | 1.64B | 1.64B |
Treasury Stock | 25.36B | 19.87B | 19.57B | 19.57B |
Retained Earnings | 34.47B | 36.56B | 35.87B | 35.11B |
Capital Surplus | 43.71B | 2.21B | 2.15B | 2.10B |
Shareholder Equity | 51.60B | 17.65B | 16.05B | 15.22B |
Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2018) (USD)
December 2018 | September 2018 | June 2018 | March 2018 | |
---|---|---|---|---|
Current Cash | 6.91B | 5.41B | 5B | 5.34B |
Receivables | 5.07B | 4.82B | 4.32B | 4.37B |
Inventory | 1.20B | 1.28B | 1.24B | 1.23B |
Current Assets | 17.16B | 14.87B | 13.87B | 14.65B |
Other Current Assets | 1.30B | 693M | 1B | 0.97B |
Short Term Investments | 1.97B | 1.42B | 1.08B | 1.43B |
Long Term Investments | 1.89B | 2.32B | 2.40B | 2.50B |
Property/Plant Equipment | 5.03B | 5.09B | 5.08B | 5.06B |
Good Will | N.A | N.A | N.A | N.A |
Intangible Assets | 1.09B | 1.11B | 1.09B | 1.12B |
Tangible Assets (Net) | -3.1B | -4.11B | -5.36B | -5.22B |
Other Assets | 1.89B | 2.01B | 2B | 1.53B |
Total Assets | 34.99B | 33.73B | 32.64B | 33.08B |
Accounts Payable | 1.89B | 1.77B | 1.87B | 1.73B |
Other Current Liabilities | 6.66B | 5.95B | 5.92B | 5.68B |
Total Current Liabilities | 10.65B | 9.69B | 9.88B | 9.62B |
Total Liabilities | 20.86B | 19.98B | 20.22B | 20.18B |
Long Term Debt | 5.65B | 5.69B | 5.67B | 5.78B |
Current Long Term Debt | 1.25B | 1.25B | 1.26B | 1.25B |
Minority Interest | -2M | 11M | 9M | 9M |
Common Stock | 1.62B | 1.63B | 1.63B | 1.63B |
Treasury Stock | 19.57B | 19.58B | 19.58B | 19.43B |
Retained Earnings | 34.07B | 33.29B | 32.04B | 32.32B |
Capital Surplus | 2.08B | 2.03B | 1.97B | 1.92B |
Shareholder Equity | 14.03B | 13.64B | 12.32B | 12.79B |
Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2017) (USD)
December 2017 | September 2017 | June 2017 | |
---|---|---|---|
Current Cash | 5.42B | 4.64B | 3.47B |
Receivables | 4.87B | 5.21B | 5.10B |
Inventory | 1.17B | 1.25B | 1.22B |
Current Assets | 14.85B | 15.05B | 14.32B |
Other Current Assets | 1.27B | 1.09B | 1.14B |
Short Term Investments | 1.39B | 2.48B | 3.04B |
Long Term Investments | 2.55B | 2.53B | 2.58B |
Property/Plant Equipment | 5B | 5.01B | 4.94B |
Good Will | N.A | N.A | N.A |
Intangible Assets | 1.21B | 1.21B | 1.25B |
Tangible Assets (Net) | -6.32B | -3.24B | -3.3B |
Other Assets | 1.47B | 0.97B | 883M |
Total Assets | 33.55B | 33.98B | 33.41B |
Accounts Payable | 2.25B | 1.70B | 1.55B |
Other Current Liabilities | 6.10B | 6.07B | 5.87B |
Total Current Liabilities | 9.56B | 9.44B | 9.02B |
Total Liabilities | 21.70B | 19.06B | 18.59B |
Long Term Debt | 6.98B | 6.98B | 6.91B |
Current Long Term Debt | N.A | N.A | 750M |
Minority Interest | -1M | 11M | 6M |
Common Stock | 1.63B | 1.64B | 1.64B |
Treasury Stock | 19.25B | 19B | 18.78B |
Retained Earnings | 31.16B | 34.14B | 33.93B |
Capital Surplus | 1.90B | 1.85B | 1.79B |
Shareholder Equity | 11.74B | 14.78B | 14.70B |
Other Liabilities | N.A | N.A | N.A |
Bristol-Myers Squibb Company cash flow (2023) (USD)
February 2023 | |
---|---|
Net Income | 2.02B |
Depreciation | 2.52B |
Changes in Receivables | 9.89B |
Changes in Inventories | 2.34B |
Cash Change | 9.25B |
Cash Flow | 3.31B |
Capital Expenditures | -346M |
Investments | N.A |
Investing Activity (other) | N.A |
Total Investing Cash Flows | 1.21B |
Dividends Paid | N.A |
Net Borrowings | 24.42B |
Other Financing Cash Flows | N.A |
Cash Flow Financing | -3.25B |
Exchange Rate Effect | N.A |
Bristol-Myers Squibb Company cash flow (2022) (USD)
October 2022 | July 2022 | |
---|---|---|
Net Income | 1.61B | 1.42B |
Depreciation | 2.59B | 2.58B |
Changes in Receivables | 9.61B | 9.05B |
Changes in Inventories | 2.07B | 2.14B |
Cash Change | 9.03B | 13.27B |
Cash Flow | 3.69B | 2.26B |
Capital Expenditures | -247M | -272M |
Investments | N.A | N.A |
Investing Activity (other) | N.A | N.A |
Total Investing Cash Flows | -2.08B | -289M |
Dividends Paid | N.A | N.A |
Net Borrowings | 24.15B | 23.22B |
Other Financing Cash Flows | N.A | N.A |
Cash Flow Financing | -4.54B | -3.52B |
Exchange Rate Effect | N.A | N.A |
Bristol-Myers Squibb Company cash flow (2021) (USD)
October 2021 | |
---|---|
Net Income | 1.55B |
Depreciation | 2.73B |
Changes in Receivables | 9.25B |
Changes in Inventories | 2.16B |
Cash Change | 15.66B |
Cash Flow | 5.27B |
Capital Expenditures | -270M |
Investments | N.A |
Investing Activity (other) | N.A |
Total Investing Cash Flows | -0.98B |
Dividends Paid | N.A |
Net Borrowings | 25.01B |
Other Financing Cash Flows | N.A |
Cash Flow Financing | -1.78B |
Exchange Rate Effect | N.A |
Bristol-Myers Squibb Company cash flow (2020) (USD)
August 2020 | June 2020 | March 2020 | |
---|---|---|---|
Net Income | -85M | -85M | -775M |
Depreciation | 5.04B | 2.56B | 2.48B |
Changes in Receivables | -435M | 501M | -724M |
Changes in Inventories | -452M | 642M | 1.45B |
Cash Change | 3.34B | 4.12B | 3.43B |
Cash Flow | 8.16B | 4.27B | 3.89B |
Capital Expenditures | -317M | -131M | -186M |
Investments | N.A | 0.92B | 659M |
Investing Activity (other) | N.A | N.A | N.A |
Total Investing Cash Flows | 1.43B | 780M | 653M |
Dividends Paid | N.A | -1.02B | -1.02B |
Net Borrowings | 22.57B | -48M | 26M |
Other Financing Cash Flows | N.A | 76M | 18M |
Cash Flow Financing | -2.05B | -0.99B | -1.05B |
Exchange Rate Effect | N.A | 60M | -67M |
Bristol-Myers Squibb Company cash flow (2019) (USD)
December 2019 | September 2019 | June 2019 | March 2019 | |
---|---|---|---|---|
Net Income | -1.06B | 1.35B | 1.43B | 1.71B |
Depreciation | 1.24B | 171M | 169M | 170M |
Changes in Receivables | -2.19B | 214M | 142M | 421M |
Changes in Inventories | 470M | -35M | -7M | 35M |
Cash Change | -17.67B | 2.09B | 21.07B | 424M |
Cash Flow | 2.04B | 2.56B | 2.08B | 1.39B |
Capital Expenditures | -251M | -190M | -191M | -204M |
Investments | -0.97B | -1.03B | 743M | 1.11B |
Investing Activity (other) | N.A | N.A | N.A | N.A |
Total Investing Cash Flows | -12.04B | 491M | 715M | 1.06B |
Dividends Paid | -668M | -671M | -671M | -669M |
Net Borrowings | 4M | 31M | 18.94B | -1.32B |
Other Financing Cash Flows | -13M | -1M | -2M | -37M |
Cash Flow Financing | -7.68B | -0.94B | 18.27B | -2.03B |
Exchange Rate Effect | 6M | -21M | 3M | 3M |
Bristol-Myers Squibb Company cash flow (2018) (USD)
December 2018 | September 2018 | June 2018 | March 2018 | |
---|---|---|---|---|
Net Income | 1.19B | 1.90B | 373M | 1.49B |
Depreciation | 172M | 165M | 157M | 143M |
Changes in Receivables | -251M | -492M | 51M | 495M |
Changes in Inventories | -64M | -30M | -118M | -4M |
Cash Change | 1.50B | 409M | -343M | -79M |
Cash Flow | 2.43B | 1.28B | 1.06B | 1.18B |
Capital Expenditures | -290M | -224M | -198M | -239M |
Investments | -317M | -242M | 476M | 157M |
Investing Activity (other) | N.A | N.A | N.A | N.A |
Total Investing Cash Flows | -336M | -147M | -348M | -43M |
Dividends Paid | -653M | -653M | -654M | -653M |
Net Borrowings | 74M | -71M | -207M | -344M |
Other Financing Cash Flows | 1M | 4M | -1M | -58M |
Cash Flow Financing | -578M | -720M | -1.02B | -1.22B |
Exchange Rate Effect | -12M | -3M | -37M | 11M |
Bristol-Myers Squibb Company cash flow (2017) (USD)
December 2017 | September 2017 | June 2017 | |
---|---|---|---|
Net Income | -2.33B | 845M | 0.92B |
Depreciation | 197M | 188M | 211M |
Changes in Receivables | 341M | -115M | -115M |
Changes in Inventories | -36M | 65M | 13M |
Cash Change | 777M | 1.17B | -440M |
Cash Flow | 1.12B | 1.71B | 1.58B |
Capital Expenditures | -254M | -262M | -248M |
Investments | 1.11B | 620M | -717M |
Investing Activity (other) | N.A | N.A | N.A |
Total Investing Cash Flows | 1.02B | 142M | -1.02B |
Dividends Paid | -639M | -640M | -643M |
Net Borrowings | -471M | 148M | -366M |
Other Financing Cash Flows | 7M | 6M | 3M |
Cash Flow Financing | -1.35B | -706M | -1.01B |
Exchange Rate Effect | -7M | 25M | 6M |
Bristol-Myers Squibb Company dividends (USD)
Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
---|---|---|---|---|---|---|
05-01-2023 | 01-02-2023 | 06-01-2023 | N.A | 0.57 | Ordinary Shares | Quarterly |
06-10-2022 | 01-11-2022 | 07-10-2022 | N.A | 0.54 | Ordinary Shares | Quarterly |
30-06-2022 | 01-08-2022 | 01-07-2022 | N.A | 0.54 | Ordinary Shares | Quarterly |
30-09-2021 | 01-11-2021 | 01-10-2021 | N.A | 0.49 | Ordinary Shares | Quarterly |
31-12-2020 | 01-02-2021 | 04-01-2021 | N.A | 0.49 | Ordinary Shares | Quarterly |
01-10-2020 | 02-11-2020 | 02-10-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
01-10-2020 | 02-11-2020 | 02-10-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
02-07-2020 | 03-08-2020 | 06-07-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
02-04-2020 | 01-05-2020 | 03-04-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
02-01-2020 | 03-02-2020 | 03-01-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
03-10-2019 | 01-11-2019 | 04-10-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
03-07-2019 | 01-08-2019 | 05-07-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
04-04-2019 | 01-05-2019 | 05-04-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
03-01-2019 | 01-02-2019 | 04-01-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
04-10-2018 | 01-11-2018 | 05-10-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
05-07-2018 | 01-08-2018 | 06-07-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
05-04-2018 | 01-05-2018 | 06-04-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
04-01-2018 | 01-02-2018 | 05-01-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
05-10-2017 | 01-11-2017 | 06-10-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
05-07-2017 | 01-08-2017 | 07-07-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
05-04-2017 | 01-05-2017 | 07-04-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
04-01-2017 | 01-02-2017 | 06-01-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
05-10-2016 | 01-11-2016 | 07-10-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
29-06-2016 | 01-08-2016 | 01-07-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
30-03-2016 | 02-05-2016 | 01-04-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
30-12-2015 | 01-02-2016 | 04-01-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
30-09-2015 | 02-11-2015 | 02-10-2015 | N.A | 0.37 | Ordinary Shares | Quarterly |
01-07-2015 | 03-08-2015 | 06-07-2015 | N.A | 0.37 | Ordinary Shares | Quarterly |
Total Valuation
Bristol-Myers Squibb Co. has a market cap or net worth of $142.35 billion. The enterprise value is $172.42 billion.
Important Dates
Share Statistics
Bristol-Myers Squibb Co. has 2.10 billion shares outstanding.
Valuation Ratios
The trailing PE ratio is 22.4991 and the forward PE ratio is 8.3787. Bristol-Myers Squibb Co.'s PEG ratio is -4.1949.
Stock Price Statistics
The stock price has decreased by -0.0519%. The beta is 0.2927, so Bristol-Myers Squibb Co.'s price volatility has been lower than the market average.
Income Statement
In the last 12 months, Bristol-Myers Squibb Co. had revenue of $46.16 billion and earned $36.02 billion in profits. Earnings per share was $2.95.